Compare Summit Therapeutics Inc (SMMT) vs Essential Utilities Inc. Common Stock (WTRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Essential Utilities Inc. Common Stock — how do they compare? Summit Therapeutics Inc trades at $15.02 (market cap $12.38B), while Essential Utilities Inc. Common Stock trades at $39.82 (market cap $11.15B). The key difference: Summit Therapeutics Inc and Essential Utilities Inc. Common Stock are close in size by market cap, and Essential Utilities Inc. Common Stock pays a 3.67% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Essential Utilities Inc. Common Stock for 0 Days on average.
| SMMT | WTRG | |
|---|---|---|
Market Cap | $12.38B | $11.15B |
Volume | 7,111,626 | 1,760,234 |
Sector | Health | Utilities |
52-Week High | $26.38 | $42.00 |
52-Week Low | $12.43 | $36.25 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $11.71B | $19.66B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.52, down 9.4% today but remains volatile following recent positive developments. The stock shows a bullish technical signal with strong moving average support and neutral oscillators. Fundamentally, the company reports no revenue and significant losses (-$1.08B net income for 2025), but recent news includes a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, driving investor optimism.
The outlook is cautiously optimistic due to strong analyst support (65% buy ratings) and a $29.33 consensus price target, representing significant upside. Key risks include ongoing cash burn, lack of current revenue, and clinical trial execution. The AstraZeneca partnership provides substantial validation and funding, but investors should monitor upcoming Q3 2026 earnings and clinical milestones for sustained momentum.
WTRG trades at $39.29, up 0.36% with neutral technical signals. The stock shows mixed earnings performance with two beats and one miss in recent quarters, while maintaining strong profitability margins (21.6% net income margin). Analyst consensus is bullish with a $44.50 price target, supported by ongoing acquisitions and pending merger developments with American Water.
The stock presents a stable utility investment with moderate growth potential through strategic acquisitions, though near-term earnings volatility and integration risks from the pending merger warrant caution. Current valuation at 20.15 P/E appears reasonable given the company's consistent cash flow generation and defensive sector positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Essential Utilities Inc. Common Stock
Essential Utilities Inc. is a holding company for regulated water, wastewater, and natural gas utilities, operating under the Aqua and Peoples brands. It serves customers across Pennsylvania, Ohio, Texas, Illinois, North Carolina, New Jersey, Indiana, Virginia, and Kentucky.
Read more on WTRG →
